ADMA: ADMA Biologics Inc Price to Sales

Corporate company logo of ADMA Biologics Inc (ADMA)

Active recruitment of biochemists and the retention of R&D staff confirm that ADMA Biologics is in an expansion phase. The price-to-sales ratio dynamics reflect investor reaction, with the parameter stabilizing at 5.70. Growth is supported by a closed-loop immunoglobulin production cycle and AI-driven plasma purification robotics, which minimize human error and guarantee drug sterility.

P/S Multiple: ADMA Biologics Inc (ADMA) for 07/04/2022 - 11/13/2026

Analytical breakdowns for ADMA Bio (ADMA)

- stock price and consensus target price:
Share Price admabiologics.com|ADMA - Analyst Consensus Forecast
- market capitalization information:
Market Value ADMA Bio|ADMA - Enterprise Value
- shareholders' equity book value data:
Book Value per Share ADMA Biologics|ADMA - Book Capitalization|Capitalization to Book Value Ratio admabiologics.com|ADMA - Aggregate Company Assets
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio ADMA Biologics|ADMA - Long-Term Debt to Capital|Short-Term Debt to Capital ADMA Corp|ADMA - Company Total Debt|Debt to Net Assets Ratio ADMA Bio|ADMA - Company Long-Term Debts|Company Short-Term Debt ADMA Biologics|Interim Coverage Ratio admabiologics.com
- company profitability and valuation multiples indicators:
ADMA - Company Net Income|Expected Net Profit ADMA Biologics|ADMA - Price to Earnings Ratio|Future Price to Earnings ADMA Biologics Inc|ADMA - Price/Earnings to Growth Ratio|Company Value to EBITDA ADMA Bio|ADMA - Operating profit EBITDA|Net earnings per share for the trailing year ADMA Biologics|ADMA - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months admabiologics.com|ADMA - Earnings growth in current year|Expected earnings per share growth for next year ADMA Biologics
- issuer revenue and sales details:
ADMA - Company Revenue|Company Future Sales admabiologics.com|ADMA - P/S Multiple|Forward P/S Multiple ADMA Bio
Summary company analytics:admabiologics.com, ADMA
Original product of ADMA Bio

The P/S ratio determines the market value of one dollar of revenue, allowing an investor to assess the degree of overpayment for a business before deducting expenses. By analyzing the price-to-sales valuation, one can understand the extent to which the market awards a premium to ADMA Biologics (ADMA) for its technological leadership in immunoglobulin synthesis and unique drug screening methods for immunodeficient patients.

Competing companies

argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|Protagonist Therapeutics Inc - P/S Multiple|IMVT - P/S Multiple|KNSA: P/S Multiple|Market Cap to Revenue Ratio GRFS|Price-to-Revenue Ratio Adaptive Biotechnologies Corporation|Market Cap to Revenue Celldex Therapeutics Inc (CLDX)|P/S Multiple AUPH|P/S Multiple BioCryst Corp (BCRX)|Vera Therapeutics, Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio DNTH|Pharvaris - P/S Multiple|ABCL: Price-to-Revenue Ratio|TRML: P/S Multiple|PGEN - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Pharming Group N.V.|Price to Sales nektar.com NKTR|Price-to-Revenue Ratio Upstream Bio (UPB)|Price-to-Revenue Ratio ZBIO (Zenas Bio)|Price-to-Revenue Ratio Immunome Corp IMNM|Gossamer Bio Corp. (GOSS) - Price to Sales|KalVista Pharmaceuticals - P/S Multiple|Price-to-Revenue Multiple septerna.com (SEPN)|PVLA: P/S Multiple|SVRA - Price-to-Revenue Coefficient|RIGL (Rigel Pharmaceuticals Inc) - P/S Multiple|Market Cap to Revenue AnaptysBio Inc. (ANAB)|Price-to-Revenue Ratio Astria Therapeutics (ATXS)|Price-to-Revenue Coefficient engene.com|P/S Multiple RAPT (RAPT Therapeutics)|P/S Multiple Aerovate Therapeutics, Inc. JBIO|Aclaris - P/S Multiple|KYTX (Kyverna Therapeutics, Inc) - Market Cap to Revenue Ratio|Tiziana Life Sciences (TLSA) - Price-to-Revenue Ratio|Market Cap to Revenue cabalettabio.com|VTYX (Ventyx Biosciences, Inc.) - P/S Multiple|P/S Multiple Theratechnologies, Inc.|Price-to-Revenue Ratio Avalo Therapeutics Inc. (AVTX)|ELDN: Price-to-Sales Ratio|P/S Multiple AGEN (Agenus)|Market Capitalization-to-Revenue Ratio CLYM|Zura Bio - P/S Multiple|ATYR - P/S Multiple|adagene.com (ADAG) - Price-to-Revenue Ratio|Ikena Oncology - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Shattuck Labs Inc|Market Cap to Revenue Equillium Bio (EQ)|P/S Multiple CNTB|P/S Multiple immunic-therapeutics.com (IMUX)|Atara Bio - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio IFRX|X4 Pharmaceuticals - P/S Multiple|Price-to-Revenue Coefficient Adicet Bio ACET|celularity.com (CELU) - Price-to-Revenue Ratio|Market Cap to Revenue INmune Bio Inc|Price-to-Revenue Ratio Barinthus Bio|Market Cap to Revenue Kezar Life Sciences Inc (KZR)|Market Cap to Revenue SABS (SAB Biotherapeutics)|P/S Multiple akaritx.com (AKTX)|Price-to-Revenue Ratio Enlivex Therapeutics Ltd. ENLV|QTTB: Market Cap to Revenue Ratio|GeoVax Labs Inc - P/S Multiple|Price to Sales Edesa Biotech Corp|IBIO: P/S Multiple|Carisma Therapeutics Inc. (CARM) - P/S Multiple|XTLB (XTL Biopharmaceuticals Ltd.) - P/S Multiple|Market Cap to Revenue Ratio BOLT (Bolt Bio)|Price-to-Revenue Ratio HCW Biologics Inc. (HCWB)|Market Cap to Revenue aptevotherapeutics.com APVO|P/S Multiple AIM (AIM ImmunoTech Inc.)|P/S Multiple Aditxt Inc. ADTX|GRI: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio XRTX (XORTX Therapeutics Inc)|HIND: P/S Multiple|REVB (Revelation Biosciences Corp) - Price-to-Revenue Ratio|INDP (Indaptus Therapeutics) - P/S Multiple|scinai.com (SCNI) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio CalciMedica, Inc. (CALI)|AFMD - Price to Sales|Price-to-Revenue Ratio Allakos ALLK|HOOKIPA Pharma, Inc. - Price-to-Revenue Ratio|IGMS - Price-to-Revenue Ratio|Price to Sales iteostherapeutics.com|OCEA: P/S Multiple|Price-to-Revenue Multiple TC BioPharm (Holdings) Plc TCBP|THRD (Third Harmonic Bio, Inc) - P/S Multiple